Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › fluticasone propionate

fluticasone propionate

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of fluticasone propionate

48 trials tracked of fluticasone propionate: 33 in phase 3 or 4 and 4 with published results. The most-cited published study has 105 citations.

48Trials tracked
33Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 13 Phase 3 20 Phase 2 9 Phase 1 3 Other / NA 3
  1. Phase 3 Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device Completed · 105 cited
  2. Phase 3 A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma Completed · 19 cited
  3. Phase 4 A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease Completed · 15 cited
  4. Phase 3 Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety Completed · 3 cited
  5. Phase 4 Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids Completed
  6. Phase 4 A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise Completed
Show 42 more trials
  1. Phase 4 Cardiovascular Function in COPD Patients Completed
  2. Phase 4 The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus Completed
  3. Phase 4 Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis Completed
  4. Phase 4 Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis) Completed
  5. Phase 4 A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis Completed
  6. Phase 4 The Effects of Montelukast on Smokers With Asthma Completed
  7. Phase 4 Vitamin D Plus Fluticasone Propionate Completed
  8. Phase 4 SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults Completed
  9. Phase 4 Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease Completed
  10. Phase 4 A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber Completed
  11. Phase 3 12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device Completed
  12. Phase 3 Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001) Completed
  13. Phase 3 Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler Completed
  14. Phase 3 Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video Completed
  15. Phase 3 Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents Completed
  16. Phase 3 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed
  17. Phase 3 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed
  18. Phase 3 Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study Completed
  19. Phase 3 Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA) Completed
  20. Phase 3 Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911) Completed
  21. Phase 3 Assessment of Fluticasone Propionate on Ocular Allergy Symptoms Completed
  22. Phase 3 Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER) Completed
  23. Phase 3 Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps Completed
  24. Phase 3 A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed
  25. Phase 3 A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma Completed
  26. Phase 3 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies Completed
  27. Phase 3 Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients Completed
  28. Phase 2 Targeted Therapy of Bronchiolitis Obliterans Syndrome Completed
  29. Phase 2 BI 671800 ED in Steroid-naive Asthmatic Patients Completed
  30. Phase 2 Enhancement of in-Vitro GC Function in Patients With COPD Completed
  31. Phase 2 Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis Completed
  32. Phase 2 Personalized Treatment Algorithms for Difficult-to-treat Asthma Completed
  33. Phase 2 Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis Completed
  34. Phase 2 Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma Completed
  35. Phase 2 A Dose-ranging Study of Fluticasone Furoate (FF) Completed
  36. Phase 2 Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma Completed
  37. Phase 1 Study to Assess the Absorption and Tolerability of Intranasal Ketorolac Tromethamine and to Assess the Effects of Oxymetazoline Hydrochloride and Fluticasone Propionate on the Absorption and Tolerability of Intranasal Ketorolac Tromethamine in Participants With Allergic Rhinitis Completed
  38. Phase 1 Open Label Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine Following Fluticasone Propionate in Healthy Subjects Completed
  39. Phase 1 Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate Completed
  40. N/A Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to <4 Years Completed
  41. N/A Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population Completed
  42. N/A Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers: Effect of Inhaled Glucocorticosteroid Treatment Completed

Showing the 48 most-cited and recently-updated of 48 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.